NASDAQ:PLSE Pulse Biosciences (PLSE) Stock Price, News & Analysis $53.87 +3.26 (+6.44%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$53.89 +0.02 (+0.04%) As of 09/18/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Pulse Biosciences Stock (NASDAQ:PLSE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pulse Biosciences alerts:Sign Up Key Stats Today's Range$50.25▼$54.2950-Day Range$25.46▼$55.2052-Week Range$12.56▼$58.90Volume867,490 shsAverage Volume622,669 shsMarket Capitalization$3.81 billionP/E RatioN/ADividend YieldN/APrice Target$45.25Consensus RatingModerate Buy Company Overview Pulse Biosciences, Inc. is a medical technology company developing proprietary bioelectric therapies based on its Nano-Pulse Stimulation technology. The platform delivers ultrashort electrical pulses designed to affect targeted cells while limiting thermal damage to surrounding noncellular tissue. The company’s primary product is the CellFX System, which is designed to deliver Nano-Pulse Stimulation treatments for certain dermatological conditions. Pulse Biosciences is also developing additional applications for its technology in areas including cardiac procedures and other medical specialties. Pulse Biosciences was founded in 2014 and is headquartered in Hayward, California. The company’s products and development programs are subject to regulatory approvals and clearances in the markets where they are offered. Its shares trade on the Nasdaq under the symbol PLSE.AI Generated. May Contain Errors. Read More Pulse Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScorePLSE MarketRank™: Pulse Biosciences scored higher than 37% of companies evaluated by MarketBeat, and ranked 729th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingPulse Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Downside RiskPulse Biosciences has a consensus price target of $45.25, representing about 16.0% downside from its current price of $53.87.Amount of Analyst CoveragePulse Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pulse Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pulse Biosciences are expected to decrease in the coming year, from ($1.29) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulse Biosciences is -45.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulse Biosciences is -45.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulse Biosciences has a P/B Ratio of 45.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pulse Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.34% of the float of Pulse Biosciences has been sold short.Short Interest Ratio / Days to CoverPulse Biosciences has a short interest ratio ("days to cover") of 7.94.Change versus previous monthShort interest in Pulse Biosciences has recently increased by 12.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPulse Biosciences does not currently pay a dividend.Dividend GrowthPulse Biosciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.74 News SentimentPulse Biosciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Pulse Biosciences this week, compared to 3 articles on an average week.Search Interest12 people have searched for PLSE on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Pulse Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $199,931.00 in company stock, which represents 0.0052% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Pulse Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $199,931.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders74.00% of the stock of Pulse Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.95% of the stock of Pulse Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pulse Biosciences' insider trading history. Receive PLSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLSE Stock News HeadlinesPulse Biosciences Completes Enrollment in 100-Patient Thyroid Nodule StudySeptember 16 at 2:59 PM | finance.yahoo.comPulse Biosciences consensus price target increased 12.27% to $51.82September 16 at 3:55 AM | msn.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.September 19 at 1:00 AM | Banyan Hill Publishing (Ad)Brokerages Set Pulse Biosciences, Inc (NASDAQ:PLSE) Price Target at $45.25September 16 at 2:58 AM | americanbankingnews.comPulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid NodulesSeptember 15, 2026 | finance.yahoo.comPulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid NodulesSeptember 15, 2026 | businesswire.comInsider Buying: Pulse Biosciences (NASDAQ:PLSE) COO Acquires $49,971.20 in StockSeptember 3, 2026 | insidertrades.comLiane Rae Teplitsky Purchases 1,036 Shares of Pulse Biosciences (NASDAQ:PLSE) StockAugust 29, 2026 | insidertrades.comSee More Headlines PLSE Stock Analysis - Frequently Asked Questions How have PLSE shares performed this year? Pulse Biosciences' stock was trading at $13.73 on January 1st, 2026. Since then, PLSE stock has increased by 292.4% and is now trading at $53.87. How were Pulse Biosciences' earnings last quarter? Pulse Biosciences, Inc (NASDAQ:PLSE) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by $0.07. The business earned $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative trailing twelve-month return on equity of 94.42% and a negative net margin of 6,755.78%. Read the conference call transcript. When did Pulse Biosciences IPO? Pulse Biosciences (PLSE) raised $20 million in an initial public offering on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO. Who are Pulse Biosciences' major shareholders? Top institutional shareholders of Pulse Biosciences include BlackRock Inc. (2.12%), Bank of America Corp DE (2.09%), Panoramic Capital LLC (0.14%) and Wellington Management Group LLP (0.11%). Insiders that own company stock include Robert W Duggan, Darrin Uecker, Mitchell E Levinson, Mitchell E Levinson, Burke Thomas Barrett, Kevin Patrick Danahy, Paul A Laviolette and Liane Rae Teplitsky. View institutional ownership trends. How do I buy shares of Pulse Biosciences? Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pulse Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pulse Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and Jabil (JBL). Company Calendar Last Earnings8/06/2026Today9/18/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PLSE's financial health is in the Green zone, according to TradeSmith. PLSE has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:PLSE CIK1625101 Webwww.pulsebiosciences.com Phone(510) 906-4600FaxN/AEmployees116Year Founded2014Price Target and Rating Average Price Target for Pulse Biosciences$45.25 High Price Target$58.00 Low Price Target$35.00 Potential Upside/Downside-16.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$72.78 million Net Margins-6,755.78% Pretax Margin-6,755.78% Return on Equity-94.42% Return on Assets-79.96% Debt Debt-to-Equity RatioN/A Current Ratio9.63 Quick Ratio9.61 Sales & Book Value Annual Sales$350 thousand Price / Sales10,897.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.19 per share Price / Book45.27Miscellaneous Outstanding Shares70,800,000Free Float18,408,000Market Cap$3.81 billion OptionableOptionable Beta1.63 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:PLSE) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulse Biosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulse Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
